Outsourcing Pharma

JANUARY 7, 2021

A leader from the chemical manufacturing firm notes pharma companies are showing increased interest in contracting out their manufacturing functions.

Reagent 62

Reagent Pharma Companies Manufacturing Contract Manufacturing 62

pharmaphorum

JANUARY 25, 2022

The Toronto-based company already counts many of the world’s largest pharma companies among its customers, using its platform for a range of tasks such as improving reagent and antibody selection to help scientists run more successful experiments, drawing on data from published studies and organisations’ internal databases.

Life Science 52

Life Science Pharma Companies Reagent Scientist 52

XTalks

AUGUST 18, 2020

Instead of RNA extraction, the Yale test involves use of a reagent that when mixed with a saliva sample and heated for a short period of time, releases the viral genome for subsequent detection with PCR. Having a test that requires less reagents and resources, such as the RNA extraction kits, increases capabilities for increased testing.

FDA Approval 90

FDA Approval Reagent RNA Genome 90

Drug Discovery World

SEPTEMBER 29, 2022

Minimising reagent consumption and costs. Company Z must ask questions to assess the four stages of their drug discovery project: How long will it take to develop an assay suitable for screening? How much time to prepare sufficient materials and reagents for screening? Completing the project by a defined deadline.

Reagent 52

Reagent DNA Scientist Drugs 52

Drug Discovery World

APRIL 3, 2023

Addressing this need in the market has allowed us penetration to work with 75% of the top twenty pharma companies. This project still acts as a robust proof-of-concept for the potential of our technology in diagnostics and as assay reagents. Does the use of automation allow the company to maintain lower staff levels?

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52

XTalks

OCTOBER 1, 2020

Moreover, Dr. Lin explains that in an academic lab, you are supposed to do everything – from ordering reagents, to washing dishes to doing an in vitro study for a project and then the in vivo work, through to completion. But in companies, you cannot do that. Now she says that she completely appreciates the focus of industry.

Scientist 52

Scientist In-Vitro Research Life Science 52

The Pharma Data

OCTOBER 14, 2020

Under the terms of the non-exclusive agreement FASMAC acquires the right to use CRISPR/Cas9 technology and commercialize tools and reagents associated with it. ERS Genomics – Ireland’s ERS Genomics signed an agreement with FASMAC Co., Ltd of Japan.

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing Trials 52